Abstract
A key aim of serosurveillance during the coronavirus disease 2019 (COVID-19) pandemic has been to estimate the prevalence of prior infection, by correcting crude seroprevalence against estimated test performance for polymerase chain reaction (PCR)-confirmed COVID-19. We show that poor generalizability of sensitivity estimates to some target populations may lead to substantial underestimation of case numbers.
Original language | English |
---|---|
Pages (from-to) | e357-e360 |
Number of pages | 4 |
Journal | Clinical Infectious Diseases |
Volume | 75 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jul 2022 |
Externally published | Yes |
Keywords
- antibody
- COVID-19
- sensitivity
- serology
- surveillance